Literature DB >> 12658273

Natural versus adaptive regulatory T cells.

Jeffrey A Bluestone1, Abul K Abbas.   

Abstract

The regulation of immune responses to self-antigens is a complex process that involves maintaining self-tolerance while retaining the capacity to mount robust immune responses against invading microorganisms. Over the past few years, many new insights into this process have been gained, leading to the re-emergence of the idea that regulatory T (T(Reg)) cells are a central mechanism of immune regulation. These insights have raised fundamental questions concerning what constitutes a T(Reg) cell, where they develop and what signals maintain T(Reg)-cell populations in a functional state. Here, we propose the existence of two subsets of CD4+ T(Reg) cells--natural and adaptive--that differ in terms of their development, specificity, mechanism of action and dependence on T-cell receptor and co-stimulatory signalling.

Entities:  

Mesh:

Year:  2003        PMID: 12658273     DOI: 10.1038/nri1032

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  420 in total

1.  CD46 engagement on human CD4+ T cells produces T regulatory type 1-like regulation of antimycobacterial T cell responses.

Authors:  Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

Review 2.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

5.  Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease.

Authors:  Silke Paust; Linrong Lu; Nami McCarty; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-02       Impact factor: 11.205

6.  The role of sildenafil in the development of transplant arteriosclerosis in rat aortic grafts.

Authors:  Shuai Luo; Mei Yang; Hao Jin; Zi-Qiang Xu; Yi-Fu Li; Peng Xia; Yi-Rrong Yang; Bi-Cheng Chen; Yan Zhang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

7.  GM-CSF-induced CD11c+CD8a--dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis.

Authors:  Balaji B Ganesh; Donald M Cheatem; Jian Rong Sheng; Chenthamarakshan Vasu; Bellur S Prabhakar
Journal:  Int Immunol       Date:  2009-01-27       Impact factor: 4.823

8.  Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Authors:  N I Rallón; M López; V Soriano; J García-Samaniego; M Romero; P Labarga; P García-Gasco; J González-Lahoz; J M Benito
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

Review 9.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 10.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.